Massive study checks if ozempic protects hearts and kidneys better than other diabetes meds

NCT ID NCT07456774

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This large study looks back at medical records of 100,000 Chinese patients with type 2 diabetes to compare heart and kidney outcomes between those taking Ozempic and those on other diabetes drugs. Researchers will track major heart problems, strokes, and kidney events. The goal is to see if Ozempic offers extra protection beyond blood sugar control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (Ozempic)
What this could lead to: If results show Ozempic is better for heart and kidney health, it could guide doctors in choosing diabetes treatments.
What could go wrong: This is a retrospective study, so it can't prove cause and effect. Results may be influenced by other factors and may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

NIS- Tianjin Medical University Chu Hsien-I Memorial Hospital-Department of Endocrinology

Tianjin, Tianjin Municipality, 300074, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.